Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial.

Aranzazu CampoJosé María González-RuizEnrique AndreuAna B AlcaideMaría M OcónJuan Pablo de-TorresJesús PueyoRosa CordovillaEva VillaronFermín Sanchez-GuijoMiguel BarruecoJorge Nuñez-CórdobaFelipe PrósperJavier J Zulueta

Published in: ERJ open research (2021)

The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.

Keyphrases

end stage renal disease
idiopathic pulmonary fibrosis
bone marrow
ejection fraction
newly diagnosed
mesenchymal stem cells
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells
low dose
gene expression
copy number
platelet rich plasma